IL292657A - Therapeutic history of interleukin-22 - Google Patents
Therapeutic history of interleukin-22Info
- Publication number
- IL292657A IL292657A IL292657A IL29265722A IL292657A IL 292657 A IL292657 A IL 292657A IL 292657 A IL292657 A IL 292657A IL 29265722 A IL29265722 A IL 29265722A IL 292657 A IL292657 A IL 292657A
- Authority
- IL
- Israel
- Prior art keywords
- interleukin
- therapeutic derivatives
- therapeutic
- derivatives
- Prior art date
Links
- 102100030703 Interleukin-22 Human genes 0.000 title 1
- 108010074109 interleukin-22 Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19207766.7A EP3819307A1 (en) | 2019-11-07 | 2019-11-07 | Therapeutic derivatives of interleukin-22 |
| PCT/EP2020/081523 WO2021089875A1 (en) | 2019-11-07 | 2020-11-09 | Therapeutic derivatives of interleukin-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL292657A true IL292657A (en) | 2022-07-01 |
Family
ID=68502950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL292657A IL292657A (en) | 2019-11-07 | 2022-05-01 | Therapeutic history of interleukin-22 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US11806403B2 (enExample) |
| EP (2) | EP3819307A1 (enExample) |
| JP (2) | JP2023502005A (enExample) |
| KR (1) | KR20220097921A (enExample) |
| CN (2) | CN118359699A (enExample) |
| AU (1) | AU2020378648A1 (enExample) |
| BR (1) | BR112022008497A2 (enExample) |
| CA (1) | CA3160338A1 (enExample) |
| CL (1) | CL2022001185A1 (enExample) |
| CO (1) | CO2022005889A2 (enExample) |
| CR (1) | CR20220249A (enExample) |
| GE (2) | GEAP202415970A (enExample) |
| IL (1) | IL292657A (enExample) |
| MX (1) | MX2022005547A (enExample) |
| MY (1) | MY209488A (enExample) |
| PE (1) | PE20221279A1 (enExample) |
| PH (1) | PH12022551107A1 (enExample) |
| SA (1) | SA522432487B1 (enExample) |
| WO (1) | WO2021089875A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3819307A1 (en) | 2019-11-07 | 2021-05-12 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
| WO2021207662A1 (en) * | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
| CN115955976A (zh) * | 2020-04-17 | 2023-04-11 | 小利兰·斯坦福大学董事会 | 工程化白介素-22多肽及其用途 |
| EP4389138A1 (en) | 2022-12-22 | 2024-06-26 | Cytoki Pharma ApS | Dosage regimen for interleukin-22 derivatives |
| JP2025542282A (ja) | 2022-12-22 | 2025-12-25 | サイトカイ・ファーマ・アーペーエス | インターロイキン－２２誘導体の投薬レジメン |
| CN119708194A (zh) * | 2023-09-28 | 2025-03-28 | 南京诺艾新生物技术有限公司 | Il-22突变体及其制备方法与应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR106F (enExample) | 1964-12-21 | |||
| CA2718634A1 (en) | 2008-03-21 | 2009-09-24 | Wyeth Llc | Antibodies against interleukin-10-like cytokines and uses therefor |
| TW201143790A (en) * | 2010-05-13 | 2011-12-16 | Univ Indiana Res & Tech Corp | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
| JP2013533227A (ja) * | 2010-06-08 | 2013-08-22 | ノヴォ ノルディスク アー／エス | Ｆｇｆ２１類似体および誘導体 |
| ES2800983T3 (es) * | 2010-12-22 | 2021-01-07 | Baxalta GmbH | Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína |
| TW201315739A (zh) * | 2011-07-01 | 2013-04-16 | 拜耳智慧財產有限公司 | 鬆弛素（ｒｅｌａｘｉｎ）融合多肽類及其用途 |
| CA2878825A1 (en) | 2012-07-10 | 2014-01-16 | The Uab Research Foundation | Compositions and methods for modulation of il-20 family cytokine activity |
| PL2970422T3 (pl) | 2013-03-15 | 2018-09-28 | F.Hoffmann-La Roche Ag | Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania |
| WO2015038938A1 (en) * | 2013-09-13 | 2015-03-19 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
| US10695406B2 (en) | 2014-05-27 | 2020-06-30 | The University Of Queensland | Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent |
| MA41794A (fr) * | 2015-03-18 | 2018-01-23 | The California Institute For Biomedical Res | Agents thérapeutiques modifiés et compositions associées |
| CN106146668A (zh) | 2015-04-01 | 2016-11-23 | 中国人民解放军第二军医大学 | 长效白细胞介素22的制备方法及其用途 |
| HK1257747A1 (zh) * | 2015-07-15 | 2019-10-25 | Protagonist Therapeutics Inc. | 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途 |
| IL321812A (en) * | 2017-08-03 | 2025-08-01 | Synthorx Inc | Cytokine complexes for the treatment of autoimmune diseases |
| CN111655717A (zh) | 2018-01-26 | 2020-09-11 | 豪夫迈·罗氏有限公司 | IL-22 Fc融合蛋白及使用方法 |
| EP3819307A1 (en) * | 2019-11-07 | 2021-05-12 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
| CN115955976A (zh) | 2020-04-17 | 2023-04-11 | 小利兰·斯坦福大学董事会 | 工程化白介素-22多肽及其用途 |
| US20240279297A1 (en) | 2021-05-11 | 2024-08-22 | Cytoki Pharma Aps | Therapeutic derivatives of interleukin-22 |
| EP4089107A1 (en) | 2021-05-11 | 2022-11-16 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
| EP4089108A1 (en) | 2021-05-11 | 2022-11-16 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
-
2019
- 2019-11-07 EP EP19207766.7A patent/EP3819307A1/en not_active Withdrawn
-
2020
- 2020-11-09 CR CR20220249A patent/CR20220249A/es unknown
- 2020-11-09 JP JP2022526450A patent/JP2023502005A/ja active Pending
- 2020-11-09 MY MYPI2022002375A patent/MY209488A/en unknown
- 2020-11-09 CA CA3160338A patent/CA3160338A1/en active Pending
- 2020-11-09 EP EP20800949.8A patent/EP4055035A1/en active Pending
- 2020-11-09 GE GEAP202415970A patent/GEAP202415970A/en unknown
- 2020-11-09 GE GEAP202015970A patent/GEP20257757B/en unknown
- 2020-11-09 KR KR1020227017744A patent/KR20220097921A/ko not_active Ceased
- 2020-11-09 MX MX2022005547A patent/MX2022005547A/es unknown
- 2020-11-09 BR BR112022008497A patent/BR112022008497A2/pt unknown
- 2020-11-09 CN CN202410470634.7A patent/CN118359699A/zh active Pending
- 2020-11-09 CN CN202080077355.4A patent/CN114761422B/zh active Active
- 2020-11-09 PH PH1/2022/551107A patent/PH12022551107A1/en unknown
- 2020-11-09 WO PCT/EP2020/081523 patent/WO2021089875A1/en not_active Ceased
- 2020-11-09 AU AU2020378648A patent/AU2020378648A1/en not_active Abandoned
- 2020-11-09 PE PE2022000734A patent/PE20221279A1/es unknown
-
2022
- 2022-05-01 IL IL292657A patent/IL292657A/en unknown
- 2022-05-03 SA SA522432487A patent/SA522432487B1/ar unknown
- 2022-05-04 CL CL2022001185A patent/CL2022001185A1/es unknown
- 2022-05-05 CO CONC2022/0005889A patent/CO2022005889A2/es unknown
- 2022-05-05 US US17/737,849 patent/US11806403B2/en active Active
-
2023
- 2023-04-11 JP JP2023064366A patent/JP7479539B2/ja active Active
- 2023-06-30 US US18/345,775 patent/US20230381320A1/en not_active Abandoned
- 2023-06-30 US US18/345,832 patent/US12447211B2/en active Active
-
2024
- 2024-04-05 US US18/628,440 patent/US12226487B2/en active Active
-
2025
- 2025-09-25 US US19/340,190 patent/US20260014257A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118359699A (zh) | 2024-07-19 |
| KR20220097921A (ko) | 2022-07-08 |
| US12226487B2 (en) | 2025-02-18 |
| PE20221279A1 (es) | 2022-09-05 |
| CN114761422B (zh) | 2026-01-02 |
| US20260014257A1 (en) | 2026-01-15 |
| US20240108731A1 (en) | 2024-04-04 |
| CN114761422A (zh) | 2022-07-15 |
| JP2023083380A (ja) | 2023-06-15 |
| CL2022001185A1 (es) | 2023-02-03 |
| MY209488A (en) | 2025-07-12 |
| BR112022008497A2 (pt) | 2022-07-26 |
| EP4055035A1 (en) | 2022-09-14 |
| US20230381320A1 (en) | 2023-11-30 |
| MX2022005547A (es) | 2022-07-04 |
| US11806403B2 (en) | 2023-11-07 |
| JP7479539B2 (ja) | 2024-05-08 |
| EP3819307A1 (en) | 2021-05-12 |
| US12447211B2 (en) | 2025-10-21 |
| PH12022551107A1 (en) | 2023-11-20 |
| GEAP202415970A (en) | 2024-12-25 |
| US20220347304A1 (en) | 2022-11-03 |
| SA522432487B1 (ar) | 2024-10-01 |
| CR20220249A (es) | 2022-08-19 |
| JP2023502005A (ja) | 2023-01-20 |
| WO2021089875A1 (en) | 2021-05-14 |
| GEP20257757B (en) | 2025-04-10 |
| AU2020378648A1 (en) | 2022-06-23 |
| CO2022005889A2 (es) | 2022-07-29 |
| US20240252649A1 (en) | 2024-08-01 |
| CA3160338A1 (en) | 2021-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286079B2 (en) | History of Imidazolonylquinilines and their medical uses | |
| SI4331584T1 (sl) | Terapevtske uporabe devteriranih derivatov lanifibranorja | |
| IL292810A (en) | Therapeutic compounds and methods of use | |
| ZA202206743B (en) | Therapy for the treatment of cancer | |
| GB201900702D0 (en) | Therapy | |
| IL276592A (en) | History of Subtirum | |
| GB201918541D0 (en) | Therapeutic compounds and their use | |
| EP3937938C0 (en) | NICORANDIL DERIVATIVES | |
| GB201905520D0 (en) | Compounds and their therapeutic use | |
| GB2587172B (en) | Pyronaridine or pharmaceutically acceptable salts thereof for the treatment of cancer | |
| PT3924340T (pt) | Derivados de indazolil-isoxazol para o tratamento de doenças como seja o cancro | |
| IL289338B1 (en) | Therapeutic interactions of leucomethylthioninium | |
| ZA202106250B (en) | Therapeutic uses of dulaglutide | |
| GB202006960D0 (en) | Therapeutic | |
| GB202001980D0 (en) | Therapeutic mentods | |
| GB201908885D0 (en) | Therapeutic compounds | |
| IL287135A (en) | Cancer treatment methods | |
| IL283295A (en) | gli1 inhibitors as therapeutic agents | |
| IL286198A (en) | Cancer treatment methods | |
| HK40079539A (en) | Therapeutic derivatives of interleukin-22 | |
| GB201812861D0 (en) | Methods of administering therapy | |
| GB202110329D0 (en) | Therapeutic | |
| GB201907647D0 (en) | Therapeutic methods | |
| GB201919036D0 (en) | Therapy | |
| GB201901130D0 (en) | Formulation for the treatment of tendinopathies |